Last updated on July 2019

A Phase 3 Efficacy Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer


Brief description of study

A study of zolbetuximab (IMAB362) plus mFOLFOX6 versus placebo plus mFOLFOX6 in subjects with Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Why is this study being done?

SPOTLIGHT is a new clinical study for adult patients who have any of:

  • advanced unresectable gastric or GEJ cancer
  • metastatic gastric or GEJ cancer These types of cancers have a unique set of proteins (called Claudin 18.2). We may be able to use a treatment that targets the proteins to kill the cancer cells.

For patients with one of the types of cancer listed above, mFOLFOX6 (a combination of three chemotherapies known as Oxaliplatin, Leucovorin, and Fluorouracil) is a current treatment option. This study is testing an experimental medicine called zolbetuximab (IMAB362). Zolbetuximab attaches itself to Claudin 18.2 on the cancer cells causing cancer cell death.

Patients will be assigned to one of two groups by chance and given either:

  • zolbetuximab with mFOLFOX6; or
  • a placebo with mFOLFOX6 A placebo is a treatment that looks like the experimental medicine, but contains no medicine.

The goal of the study is to find out if zolbetuximab with mFOLFOX6 helps patients to live longer by stopping the cancer from getting worse.

Detailed Study Description

The study consists of the following periods: screening; treatment; post-treatment follow up, safety follow up, long term and survival follow-up.

Clinical Study Identifier: NCT03504397

Find a site near you

Start Over

University of Arizona

Phoenix, AZ United States
  Connect »

Pacific Shores Medical Group

Huntington Beach, CA United States
  Connect »

Loma Linda University

Loma Linda, CA United States
  Connect »

Cedars-Sinai Medical Center

Los Angeles, CA United States
  Connect »

University of California Davis

Sacramento, CA United States
  Connect »

University of Miami

Miami, FL United States
  Connect »

University of Chicago

Chicago, IL United States
  Connect »

Norton Cancer Institute

Louisville, KY United States
  Connect »

Health Partners Institute

Saint Louis Park, MN United States
  Connect »

Lancaster General Hospital

Lancaster, PA United States
  Connect »

Thomas Jefferson University

Philadelphia, PA United States
  Connect »

Sanford Cancer Center

Sioux Falls, SD United States
  Connect »

Site AU61002

Douglas, Australia
  Connect »

Site AU61011

Tugun, Australia
  Connect »

Site AU61008

Adelaide, Australia
  Connect »

Site AU61006

East Bentleigh, Australia
  Connect »

Site AU61007

Kogarah, Australia
  Connect »

Site BE32007

Edegem, Belgium
  Connect »

Site BE32001

Bruxelles, Belgium
  Connect »

Site BE32002

Bruxelles, Belgium
  Connect »

Site BE32006

Leuven, Belgium
  Connect »

Site BE32005

Brugge, Belgium
  Connect »

Site BE32004

Brussels, Belgium
  Connect »

Site CA15005

Edmonton, Canada
  Connect »

Site CA15002

Montreal, QC Canada
  Connect »

Site CA15008

Montreal, QC Canada
  Connect »

Site CA15009

Saint-John, Canada
  Connect »

Site FR33010

Brest Cedex, France
  Connect »

Site FR33008

Besancon cedex, France
  Connect »

Site FR33011

Montpellier Cedex 5, France
  Connect »

Site FR33002

Paris cedex, France
  Connect »

Site FR33006

Poitiers, France
  Connect »

Site FR33007

Nice Cedex 2, France
  Connect »

Site DE49008

Munich, Germany
  Connect »

Site DE49007

Munchen, Germany
  Connect »

Site DE49015

Magdeburg, Germany
  Connect »

Site DE49004

Leipzig, Germany
  Connect »

Site DE49012

Berlin, Germany
  Connect »

Site DE49018

Dresden, Germany
  Connect »

Site DE49019

Heilbronn, Germany
  Connect »

Site IT39003

Piacenza, Italy
  Connect »

Site IT39022

Reggio Emilia,, Italy
  Connect »

Site JP81002

Matsuyama, Japan
  Connect »

Site JP81010

Kitaadachi-gun, Japan
  Connect »

Site JP81012

Sunto-gun, Japan
  Connect »

Site KR82002

Seongnam-si, Korea, Republic of
  Connect »

Site KR82009

Suwon-si, Korea, Republic of
  Connect »

Site KR82004

Seoul, Korea, Republic of
  Connect »

Site KR82008

Incheon, Korea, Republic of
  Connect »

Site KR82003

Seoul, Korea, Republic of
  Connect »

Site KR82005

Seoul, Korea, Republic of
  Connect »

Site KR82007

Seoul, Korea, Republic of
  Connect »

Site KR82006

Seoul, Korea, Republic of
  Connect »

Site PL48007

Ostroleka, Poland
  Connect »

Site PL48005

Wieliszew, Poland
  Connect »

Site PL48002

Brzozow, Poland
  Connect »

Site ES34013

Badalona, Spain
  Connect »

Site ES34011

Alcorcon, Spain
  Connect »

Site ES34005

Barcelona, Spain
  Connect »

Site ES34016

Barcelona, Spain
  Connect »

Site ES34015

Barcelona, Spain
  Connect »

Site ES34006

Zaragoza, Spain
  Connect »

Site TW88605

Kwei-Shan, Taiwan
  Connect »

Site TW88604

Kaohsiung, Taiwan
  Connect »

Site TW88603

Taichung, Taiwan
  Connect »

Site GB44003

Aberdeen, United Kingdom
  Connect »

Site GB44101

London, United Kingdom
  Connect »

Site GB44006

Edinburgh, United Kingdom
  Connect »

Site GB44102

Sutton, United Kingdom
  Connect »

Site GB44004

London, United Kingdom
  Connect »

Karmanos Cancer Institute

Detroit, MI United States
  Connect »

Site DE49010

Dresden, Germany
  Connect »

Site IT39022

Reggio Emilia, Italy
  Connect »

Site PL48001

Warszawa, Poland
  Connect »

Site GB44009

Coventry, United Kingdom
  Connect »

Site CL56003

Santiago, Chile
  Connect »

Site IL97208

Petah-Tikva, Israel
  Connect »

Site IL97203

Tel Aviv, Israel
  Connect »

Site JP81013

Bunkyo-ku, Japan
  Connect »

Site IL97206

Kfar Saba, Israel
  Connect »

Site IL97202

Jerusalem, Israel
  Connect »

Site IT39024

Turin TO, Italy
  Connect »

Site GB44001

Manchester, United Kingdom
  Connect »

Site DE49011

Berlin, Germany
  Connect »

Site GB44008

Leeds, United Kingdom
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.